Mark E. Zafereo

Nov 27, 2024 | jamanetwork.com | Sophie R. Li |Mark E. Zafereo |Steven Sherman

Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma Key PointsQuestion  Is germline genetic risk, as estimated using a polygenic score (PGS), associated with clinicopathologic characteristics and survival outcomes among patients with papillary thyroid carcinoma (PTC)?

Jul 11, 2024 | jamanetwork.com | Sarah Hamidi |Hormonal Disorders |Mark E. Zafereo |Jennifer Wang

Abstract Importance  BRAF/MEK inhibitors revolutionized the treatment of BRAF V600E-variant anaplastic thyroid carcinoma (BRAFv-ATC), offering improved outcomes for patients with this previously incurable disease. Observations  Anaplastic thyroid carcinoma (ATC) accounts for approximately half of thyroid cancer−related deaths.

May 6, 2024 | jamanetwork.com | Ali Shayanfar |Laura Boucai |Mark E. Zafereo |Maria E Cabanillas

A Review of Thyroid Cancer To the Editor A recent Review1 discussed exposure to ionizing radiation as a common risk factor for thyroid cancer. However, it is important to consider additional risk factors for thyroid cancer. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs), a class of medications used to treat type 2 diabetes, are frequently prescribed to improve glycemic control and promote weight loss.

May 6, 2024 | jamanetwork.com | Laura Boucai |Mark E. Zafereo |Maria E Cabanillas

A Review of Thyroid Cancer To the Editor A recent Review1 discussed the complexity of thyroid cancer. First, we would like to highlight the importance of distinguishing between benign and malignant thyroid nodules preoperatively.

May 6, 2024 | jamanetwork.com | Laura Boucai |Mark E. Zafereo |Maria E Cabanillas |Hormonal Disorders

A Review of Thyroid Cancer—Reply In Reply We appreciate letters about our Review on thyroid cancer.1 In response to the comments by Drs Beheshtirouy and Shayanfar, the causal association between GLP-1 RA use and thyroid cancer is complex and requires careful consideration of factors that directly or indirectly influence carcinogenesis pathways such as the direct biological effects of the drug, host susceptibility factors (eg, obesity or proinflammatory states), biases embedded in clinical...